Feeding Next‐Generation Nanomedicines to Europe: Regulatory and Quality Challenges
Source abstract
Abstract
Abstract New and innovative nanomedicines have been developed and marketed over the past half‐century, revolutionizing the prognosis of many human diseases. Although a univocal regulatory definition is not yet available worldwide, the term “nanomedicines” generally identifies medicinal products that use nanotechnology in their design or production. Due to the intrinsic high structural complexity of these products, the scientific and regulatory communities are reflecting on how to revise the regulatory framework to provide a more appropriate benefit/risk balance to authorize them on the market, considering the impact of their peculiar physicochemical features in the evaluation of efficacy and safety patterns. Herein, a critical perspective is provided on the current open issues regarding regulatory qualification and physicochemical characterization of nanosystems considering the current European regulatory framework on nanomedicine products. Practicable paths for improving their quality assurance and predicting their fate in vivo are also argued. Strengthening the multilevel alliance among academic institutions, industrial stakeholders, and regulatory authorities seems strategic to support innovation by standard approaches (e.g., qualification, characterization, risk assessment), and to expand current knowledge, also benefiting from the new opportunities offered by artificial intelligence and digitization in predictive modelling of the impact of nanomedicine characteristics on their fate in vivo.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Inhalation and Respiratory Drug Delivery · Nanoparticle-Based Drug Delivery · Biosimilars and Bioanalytical Methods
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Pharmaceutical Sciences Università degli Studi di Milano via G. Colombo Milan 71‐20133 Italy
Department of Pharmaceutical Sciences Università degli Studi del Piemonte Orientale Largo Donegani Novara 2‐28100 Italy
Department of Pharmaceutical and Pharmacological Sciences University of Padova via F. Marzolo Padova 5‐35131 Italy
References (67)
Show source-provided references
1. 10.3390/pharmaceutics1310161510.3390/pharmaceutics13101615 ↗
2. 10.1016/j.addr.2019.06.00310.1016/j.addr.2019.06.003 ↗
3. 10.1016/j.drudis.2017.01.01610.1016/j.drudis.2017.01.016 ↗
4. 10.2174/092986732866621040611552910.2174/0929867328666210406115529 ↗
5. 10.1016/j.drudis.2018.08.00310.1016/j.drudis.2018.08.003 ↗
6. 10.1016/j.ijpharm.2023.12319310.1016/j.ijpharm.2023.123193 ↗
7. Food and Drug Administration (FDA) Nanotechnology Guidance Documents https://www.fda.gov/science‐research/nanotechnology‐programs‐fda/nanotechnology‐guidance‐documents 2018 (accessed: June 2023).
8. European Medicines Agency (EMA) Multidisciplinary: Nanomedicines https://www.ema.europa.eu/en/human‐regulatory/research‐development/scientific‐guidelines/multidisciplinary/multidisciplinary‐nanomedicines 2022 (accessed: June 2023).
9. Funk F. · Int. J. Mol. Sci. · 2022 · 2140 · 23
10. 10.1016/j.scitotenv.2018.09.17810.1016/j.scitotenv.2018.09.178 ↗
11. National Institutes of Health Protocols and Capabilities from the Nanotechnology Characterization Labhttps://www.cancer.gov/nano/research/ncl/protocols‐capabilities 2023 (accessed: June 2023).
12. European Medicines Agency (EMA) Reflection Paper on the Use of Artificial Intelligence (AI) in the Medicinal Product Lifecycle EMA/CHMP/CVMP/83833/2023 2023.
13. 10.1021/acsomega.3c0059610.1021/acsomega.3c00596 ↗
14. 10.1007/s00204-023-03471-x10.1007/s00204-023-03471-x ↗
15. 10.1021/acsabm.8b0061210.1021/acsabm.8b00612 ↗
16. 10.3390/molecules2705166910.3390/molecules27051669 ↗
17. 10.1080/10408398.2016.116036310.1080/10408398.2016.1160363 ↗
18. 10.1002/adhm.20180100210.1002/adhm.201801002 ↗
19. Commission European · 2022
20. European Commission Commission Recommendation of 18.10.2011 on the Definition of Nanomaterial Text with EEA Relevance https://eur‐lex.europa.eu/legal‐content/EN/TXT/?uri=CELEX%3A32011H0696 2011 (accessed: June 2023).
21. Regulation (EC) No. 1223/2009 on Cosmetic Products https://eur‐lex.europa.eu/legal‐content/EN/TXT/?uri=CELEX%3A02009R1223‐20221217 2023 (accessed: June 2023).
22. Regulation (EU) 2017/745 on Medical Devices https://eur‐lex.europa.eu/legal‐content/EN/TXT/?uri=CELEX%3A02017R0745‐20230320 2023 (accessed: June 2023).
23. Regulation (EU) 2015/2283 on Novel Foods https://eur‐lex.europa.eu/legal‐content/EN/TXT/?uri=CELEX%3A02015R2283‐20210327 2023 (accessed: June 2023).
24. EMA Reflection Paper on Nanotechnology‐Based Medicinal Products for Human Use EMEA/CHMP/79769/2006 2006.
25. EMA Nanotechnology https://www.ema.europa.eu/en/glossary/nanotechnology 2022 (accessed: June 2023).
26. FDA Guidance for Industry Considering Whether an FDA‐Regulated Product Involves the Application of Nanotechnology https://www.fda.gov/regulatory‐information/search‐fda‐guidance‐documents/considering‐whether‐fda‐regulated‐product‐involves‐application‐nanotechnology 2014.
27. 10.1016/j.ijpharm.2012.09.03410.1016/j.ijpharm.2012.09.034 ↗
28. 10.1208/s12248-013-9532-010.1208/s12248-013-9532-0 ↗
29. 10.1016/j.jconrel.2018.11.00710.1016/j.jconrel.2018.11.007 ↗
30. 10.1016/j.ejps.2019.03.01110.1016/j.ejps.2019.03.011 ↗
31. 10.1038/s41598-018-38152-810.1038/s41598-018-38152-8 ↗
32. 10.1111/nyas.1338210.1111/nyas.13382 ↗
33. 10.1016/j.addr.2018.06.02410.1016/j.addr.2018.06.024 ↗
34. 10.1007/s13346-021-01089-z10.1007/s13346-021-01089-z ↗
35. 10.3389/fchem.2018.0036010.3389/fchem.2018.00360 ↗
36. 10.1016/j.impact.2017.09.00210.1016/j.impact.2017.09.002 ↗
37. 10.1038/nbt.327210.1038/nbt.3272 ↗
38. 10.1016/j.jconrel.2010.03.01110.1016/j.jconrel.2010.03.011 ↗
39. 10.1016/j.ejpb.2010.12.02910.1016/j.ejpb.2010.12.029 ↗
40. 10.1016/0005-2736(92)90194-Q10.1016/0005-2736(92)90194-Q ↗
41. 10.1016/j.ijpharm.2017.04.01310.1016/j.ijpharm.2017.04.013 ↗
42. 10.1080/14686996.2019.162717410.1080/14686996.2019.1627174 ↗
43. 10.1007/s40264-023-01277-510.1007/s40264-023-01277-5 ↗
44. 10.1002/adhm.20210057410.1002/adhm.202100574 ↗
45. 10.1016/j.ijpharm.2017.10.00610.1016/j.ijpharm.2017.10.006 ↗
46. 10.1016/j.jconrel.2019.02.03010.1016/j.jconrel.2019.02.030 ↗
47. ISO/PRF TS 24672 – Nanotechnologies – Guidance on the Measurement of Nanoparticle Number Concentration https://www.iso.org/standard/79369.html 2023 (accessed: June 2023).
48. ISO 21363:2020 – Nanotechnologies – Measurements of Particle Size and Shape Distributions by Transmission Electron Microscopy https://www.iso.org/standard/70762.html 2023 (accessed: August 2023).
49. ISO/TS 21362:2018 – Nanotechnologies – Analysis of Nano‐Objects Using Asymmetrical‐Flow and Centrifugal Field‐Flow Fractionation https://www.iso.org/standard/70761.html 2018 (accessed: August 2023).
50. ISO 19749:2021 – Nanotechnologies – Measurements of Particle Size and Shape Distributions by Scanning Electron Microscopy https://www.iso.org/standard/66235.html 2021 (accessed: August 2023).
51. ISO 22412:2017 – Particle Size Analysis – Dynamic Light Scattering (DLS) https://www.iso.org/standard/65410.html 2017 (accessed: August 2023).
52. European Commission Commission staff working document – Review of the Commission Recommendation 2011/696/EU on the definition of nanomaterial accompanying the document Commission Recommendation on the definition of nanomaterial SWD(2022) 150 final Brussels 2022.
53. 10.1016/j.chroma.2020.46176710.1016/j.chroma.2020.461767 ↗
54. 10.1021/acs.jpcc.1c0740910.1021/acs.jpcc.1c07409 ↗
55. 10.1007/s00216-009-2996-110.1007/s00216-009-2996-1 ↗
56. 10.1016/j.chemphyslip.2011.12.01110.1016/j.chemphyslip.2011.12.011 ↗
57. 10.1116/1.514141910.1116/1.5141419 ↗
58. 10.1039/C8NR02278J10.1039/C8NR02278J ↗
59. 10.3390/pharmaceutics1404088310.3390/pharmaceutics14040883 ↗
60. 10.1021/acsami.0c1847010.1021/acsami.0c18470 ↗
61. H.Rauscher V.Kestens K.Rasmussen T.Linsinger E.Stefaniak Guidance on the implementation of the Commission Recommendation 2022/C 229/01 on the definition of nanomaterial European Union Luxembourg2023.
62. European Nanomedicine Characterisation Laboratory (EUNCL) https://www.euncl.org/ 2023 (accessed: August 2023).
63. H.Rauscher A.Mech P.Gibson D.Gilliland A.Held V.Kestens R.Koeber T. P. J.Linsinger E.Stefaniak Identification of Nanomaterials through Measurements2019.
64. European Medicines Agency (EMA) Reflection Paper on Surface Coating: General Issues for Consideration Regarding Parenteral Administration of Coated Nanomedicine Products EMA/325027/2013 2013.
65. European Medicines Agency (EMA) Reflection Paper on the Data Requirements for Intravenous Liposomal Products Developed with Reference to an Innovator Liposomal Product EMA/CHMP/806058/2009/Rev. 02 2013.
66. European Medicines Agency (EMA) Concept Paper on the Development of a Guideline on the Quality Aspects of mRNA Vaccines EMA/CHMP/BWP/211968/2023 2023.
67. 10.1002/adhm.20190186210.1002/adhm.201901862 ↗